Human Papilloma Virus Vaccinations

Board takeaway

• Recommend age-appropriate HPV vaccination as part of anticipatory guidance and coordinate with the child’s medical provider.
• Timing: Routine vaccination is at 11–12 years and may begin at 9; series selection depends on age at the first dose and immune status.
• Evidence: Explain its protection against HPV infection and the policy’s limits on directly demonstrated oropharyngeal cancer outcomes.

Why HPV matters in dentistry

• Transmission may involve sexual or nonsexual contact, including skin-to-skin, skin-to-mouth, oral sex, and intercourse.
• Persistent high-risk HPV infection is associated with anogenital, skin, oral, and oropharyngeal cancers.
• The principal HPV-associated OOPC is oropharyngeal squamous cell carcinoma involving the tonsils or tongue base. HPV 16 predominates; other high-risk types also contribute.
• Affected patients may be younger, healthier, and have little smoking history. Absence of traditional tobacco/alcohol risk factors does not eliminate concern.

Evidence and its limits

• Population studies show substantial declines in vaccine-type HPV infection after vaccine introduction. Declines among unvaccinated people suggest herd effects.
• The reviewed evidence supports protection against oral and anal HPV infection, comparable to protection against cervical infection.
• Reduced oral infection and evidence of reduced cervical/vulvovaginal cancer risk support the hypothesis of OOPC prevention. The policy reports no studies directly demonstrating that cancer endpoint.
• Safety conclusions draw on prelicensure trials and postlicensure monitoring.

Timing and dose-count decisions

• Routine vaccination: age 11–12 years; may begin at age 9.
• Immunocompetent patients starting before age 15: two doses, 6–12 months apart.
• A three-dose series is recommended when:
  • Initial vaccination occurs at age 15 or older.
  • An immunocompromising condition is present.
  • A child aged 9–14 received two doses less than five months apart.
• Base the age threshold on age at initiation. The policy does not supply the three-dose timing or a complete catch-up algorithm; use current CDC guidance for implementation.

Decision map: HPV dose count

Loading diagram…

Dose count follows age at the first dose, not current age. Immunocompromised patients require three doses. A normally immunocompetent child starting before 15 generally needs two doses 6–12 months apart; an interval under five months requires a third. Apply the contraindication/deferral assessment below before giving a dose.

Safety: contraindication versus deferral

• Expected reactions include fever, injection-site reactions, and adolescent syncope. The policy reports no serious safety concerns identified in the reviewed monitoring data.
• Contraindication: severe allergic reaction to a vaccine component, such as baker’s yeast, or after a previous dose.
• Defer: moderate/severe acute illness until symptoms improve; vaccination is not recommended during pregnancy.
• Do not equate temporary deferral with permanent ineligibility.

Dental counseling and continuing care

• Explain HPV’s association with OOPC and other HPV-related oral lesions, along with potential vaccination benefits.
• Address barriers: safety concerns, limited knowledge, perceived lack of need, special health care needs, lack of sexual activity, and absent provider recommendation.
• Frequent dental visits provide repeated opportunities for prevention counseling. A lack of sexual activity should not be used to dismiss age-appropriate vaccination.
• Routinely examine for oral findings or changes consistent with OOPC; vaccination does not replace examination.
• Stay current with the literature and consider additional HPV-prevention approaches that reduce transmission risk.
• The policy identifies dental offices as a possible additional vaccine access point; it does not establish an administration protocol or universal requirement to deliver vaccines.

Common board traps

Answer aloud

How should you respond when a parent thinks HPV vaccination is unnecessary before sexual activity?

Recommend age-appropriate preventive vaccination before exposure, with the medical provider.

• HPV is associated with cancers, including oropharyngeal disease; nonsexual transmission also occurs.
• Routine vaccination is at 11–12 years and may begin at 9.
• Address safety concerns and perceived lack of need; continue oral examination after vaccination.

How do age at the first HPV dose and immune status determine the series?

An immunocompetent patient starting before age 15 uses two doses 6–12 months apart; older initiation or immunocompromise calls for three doses.

• Use age at initiation, not current age.
• If two doses at ages 9–14 were less than 5 months apart, a third dose is recommended.
• The AAPD policy does not give a complete three-dose/catch-up schedule; coordinate timing using CDC guidance.

A healthy 13-year-old received two HPV doses four months apart. Is that sufficient?

No. Less than five months between doses does not complete the two-dose series.

• Coordinate a third dose and its timing with the medical provider using CDC guidance.
• This is an interval problem, even though the patient began before age 15.

Which HPV vaccine concerns require contraindication versus temporary deferral?

A severe allergic reaction to a component or prior dose is a contraindication; moderate/severe acute illness and pregnancy call for deferral.

• Component example: baker's yeast.
• Resume consideration after acute illness improves; deferral is not permanent ineligibility.
• Expected reactions include fever, injection-site reactions, and adolescent syncope.

Can you guarantee HPV vaccination prevents throat cancer?

No. Explain demonstrated infection reduction and the policy's inferred oropharyngeal cancer benefit.

• The policy reports no studies directly establishing that cancer endpoint.
• Reduced oral HPV infection and evidence from other HPV-associated cancers support the prevention rationale.
• Vaccination does not replace continuing oral examination.